

Appl. No. 09/863,818  
Amdt. Dated September 26, 2003  
Reply to Office Action of March 27, 2003

**IN THE CLAIMS:**

Claims 1-20. (Cancelled).

Claim 21. (Currently amended) A binding composition comprising an antigen binding site of an antibody which specifically binds to a polypeptide comprising SEQ ID NO:12, ~~or an antigenic fragment thereof.~~

Claim 22. (Currently amended) The binding composition of Claim 21, ~~further comprising: that is:~~

- a) a humanized antibody;
- b) a polyclonal antibody;
- c) a monoclonal antibody;
- d) an Fv fragment;
- e) an Fab fragment; or
- f) an F(ab')<sub>2</sub> fragment; ~~or~~
- ~~g) a detectable label.~~

Claim 23. (Currently amended) ~~A composition comprising the~~ The binding composition of Claim 21 ~~and further~~ comprising a carrier.

Claim 24. (Currently amended) A kit comprising the binding composition of Claim 21, and:

- a) a compartment [[; or]] containing the binding composition; and
- b) ~~instructions for use~~ a source of DCRS9 (SEQ ID NO:12) as a positive control.

Appl. No. 09/863,818  
Amdt. Dated September 26, 2003  
Reply to Office Action of March 27, 2003

Claim 25. (Currently amended) A method of producing an antigen:binding composition complex, comprising contacting under appropriate conditions a polypeptide comprising SEQ ID NO:12, ~~or an antigenic fragment thereof, with a~~ with the binding composition of Claim 21, thereby allowing the complex to form.

Claim 26. (Cancelled).

Claim 27. (New) The binding composition of Claim 21, further comprising a detectable label.